Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids

Carcinogenesis

Volumn 33, Issue 1, 2012, Pages 49-58

  Correa, Rohann J M ^a,b   Peart, Teresa ^a,b   Valdes, Yudith Ramos ^a   Dimattia, Gabriel E ^a,b   Shepherd, Trevor G ^a,b  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN KINASE B; PROTEIN P130; S PHASE KINASE ASSOCIATED PROTEIN 2;

ARTICLE; ASCITES FLUID; CANCER CELL CULTURE; CANCER PATIENT; CARCINOGENESIS; CELL ADHESION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DORMANCY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; EPITHELIAL OVARIAN CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; OVARY CANCER; OVARY METASTASIS; PERITONEAL FLUID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPHEROID CELL;

EID: 84855405986     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr241     Document Type: Article

References (52)

1. Cannistra,S.A. (2004) Cancer of the ovary. N. Engl. J. Med., 351, 2519-2529.
2. Bast,R.C., Jr. et al. (2009) The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer, 9, 415-428.
3. NCI SEER. (2010) Cancer Stat Fact Sheet: Cancer of the Ovary. National Cancer Institute. http://seer.cancer.gov/statfacts/html/ovary.html.
4. Shield,K. et al. (2009) Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol. Oncol., 113, 143-148.
5. Tamsma,J.T. et al. (2001) Pathogenesis of malignant ascites: starling's law of capillary hemodynamics revisited. Ann. Oncol., 12, 1353-1357.
6. Lu,Z. et al. (2008) The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J. Clin. Invest., 118, 3917-3929.
7. Smith,E.J. et al. (1996) The accumulation of an E2F-p130 transcriptional repressor distinguishes a G0 cell state from a G1 cell state. Mol. Cell. Biol., 16, 6965-6976.
8. Litovchick,L. et al. (2007) Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence. Mol. Cell, 26, 539-551.
9. Carroll,J.S. et al. (2003) p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Res., 63, 4322-4326.
10. Rivard,N. et al. (1996) Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts. J. Biol. Chem., 271, 18337-18341.
11. Hu,J. et al. (2011) Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/RB2. Int. J. Cancer, 129, 307-318.
12. Moss,N.M. et al. (2009) Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in i.p. metastatic dissemination. Cancer Res., 69, 7121-7129.
13. Burleson,K.M. et al. (2006) Disaggregation and invasion of ovarian carcinoma ascites spheroids. J. Transl. Med., 4, 6.
14. Yoshida,Y. et al. (2008) Laminin-1-derived scrambled peptide AG73T disaggregates laminin-1-induced ovarian cancer cell spheroids and improves the efficacy of cisplatin. Int. J. Oncol., 32, 673-681.
15. Tang,M.K. et al. c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia, 12, 128-138.
16. Xing,H. et al. (2005) Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy. J. Cancer Res. Clin. Oncol., 131, 511-519.
17. Franke,T.F. (2008) PI3K/Akt: getting it right matters. Oncogene, 27, 6473-6488.
18. Campbell,I.G. et al. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res., 64, 7678-7681.
19. Levine,D.A. et al. (2005) Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res., 11, 2875-2878.
20. Philp,A.J. et al. (2001) The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res., 61, 7426-7429.
21. Wang,Y. et al. (2005) PIK3CA mutations in advanced ovarian carcinomas. Hum. Mutat., 25, 322.
22. Shayesteh,L. et al. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet., 21, 99-102.
23. Nakayama,K. et al. (2006) Sequence mutations and amplification of PIK3-CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol. Ther., 5, 779-785.
24. Obata,K. et al. (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous ormucinous epithelial ovarian tumors. Cancer Res., 58, 2095-2097.
25. Carpten,J.D. et al. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature, 448, 439-444.
26. Gao,N. et al. (2004) G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am. J. Physiol. Cell Physiol., 287, C281-C291.
27. Lane,D. et al. (2007) Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int. J. Cancer, 121, 1227-1237.
28. Lee,S. et al. (2005) Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol. Oncol., 97, 26-34.
29. Arboleda,M.J. et al. (2003) Overexpression of AKT2/protein kinase beta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res., 63, 196-206.
30. Meng,Q. et al. (2006) Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal, 18, 2262-2271.
31. Shepherd,T.G. et al. (2006) Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat. Protoc., 1, 2643-2649.
32. Shield,K. et al. (2007) Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J. Carcinog., 6, 11.
33. Iwanicki,M.P. et al. (2011) Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov, 1, 144-157.
34. Bradford,M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
35. Zhang,S. et al. (2008) Identification and characterization of ovarian cancerinitiating cells from primary human tumors. Cancer Res., 68, 4311-4320.
36. Theriault,B.L. et al. (2007) BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis, 28, 1153-1162.
37. Pinke,D.E. et al. (2008) The prognostic significance of elongation factor eEF1A2 in ovarian cancer. Gynecol. Oncol., 108, 561-568.
38. Manning,B.D. et al. (2007) AKT/PKB signaling: navigating downstream. Cell, 129, 1261-1274.
39. Lin,H.K. et al. (2009) Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat. Cell Biol., 11, 420-432.
40. Gao,D. et al. (2009) Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat. Cell Biol., 11, 397-408.
41. Bhattacharya,S. et al. (2003) SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells. Oncogene, 22, 2443-2451.
42. Sutterluty,H. et al. (1999) p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat. Cell Biol., 1, 207-214.
43. Barkan,D. et al. (2008) Inhibition of metastatic outgrowth fromsingle dormant tumor cells by targeting the cytoskeleton. Cancer Res, 68, 6241-6250.
44. Mellor,H.R. et al. (2005) A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Br. J. Cancer, 93, 302-309.
45. Daubriac,J. et al. (2009) Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates. Cell Death Differ., 16, 1146-1155.
46. Lane,D. et al. (2008) Cell detachment modulates TRAIL resistance in ovarian cancer cells by downregulating the phosphatidylinositol 3-kinase/Akt pathway. Int. J. Gynecol. Cancer, 18, 670-676.
47. Burleson,K.M. et al. (2004) Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol. Oncol., 93, 170-181.
48. Lessan,K. et al. (1999) CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am. J. Pathol., 154, 1525-1537.
49. Choi,Y.P. et al. (2011) Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Cancer Lett., 307, 62-71.
50. Karst,A.M. et al. (2010) Ovarian cancer pathogenesis: a model in evolution. J. Oncol., 2010, 932371.
51. Cooke,S.L. et al. (2010) Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene, 29, 4905-4913.
52. Tan,D.S. et al. (2011) Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin. Cancer Res., 17, 1521-1534.